Neumora reports favorable NMRA-215 toxicology data, still targets Q4 2026 IND
Neumora says a repeat rat toxicology study showed no unexpected adverse findings, keeping its plan to file an IND for NMRA-215 in obesity by year end.
SEC filing
Latest
Monday, July 27
argenx to acquire Forte Biosciences for $77 per share in cash
The immunology company will pay about $2.2 billion for Forte's anti-CD122 antibody FB102, tested in vitiligo and celiac disease.
SEC filing
AstraZeneca's Ultomiris misses main goal in adult HSCT-TMA trial
The Phase III ALXN1210-TMA-313 study failed on its primary endpoint in adults and adolescents, while a companion pediatric study showed positive survival data.
SEC filing
MapLight's ML-007C-MA hits primary endpoint, company plans confirmatory pivotal trial
The 210/3 mg BID dose reduced PANSS total scores versus placebo in Phase 2 ZEPHYR, and MapLight said it will advance to an additional pivotal study ahead of an end-of-Phase 2 FDA meeting.
SEC filing
GeoVax reaffirms Q4 start for GEO-MVA pivotal trial, reports $3.1 million cash
GeoVax said it kept working through operational steps for its EMA-backed GEO-MVA immunobridging study while advancing Gedeptin combination plans and narrowing quarterly losses.
SEC filing
Champions Oncology posts record $59.4 million fiscal 2026 revenue
The oncology research company reported four straight quarters of positive adjusted EBITDA and continued investment in radiopharmaceuticals and its data platform.
SEC filing
Jazz registers Phase 3b/4 trial testing gradual CBD-OS titration in adult LGS patients
Kyverna and ElevateBio sign commercial supply deal for miv-cel
The new agreement replaces a prior development pact and covers manufacturing for Kyverna's CAR T-cell therapy as it nears a possible U.S. approval in stiff person syndrome.
SEC filing
Ionis registers Phase 3 pediatric study of olezarsen for FCS
CAMP4 gets Australian clearance to start CMP-002 trial in SYNGAP1 disorder
The clearance also triggers a second $50 million financing tranche tied to a September 2025 private placement, with closing expected August 3, 2026.
SEC filing
Gossamer Bio reacquires worldwide seralutinib rights from Chiesi, targets September NDA
Gossamer said an FDA Pre-NDA meeting supports filing seralutinib for PAH in September 2026, after ending its collaboration with Chiesi.
SEC filing
SELLAS loses arbitration against 3D Medicines over GPS milestone dispute
An HKIAC arbitrator sided with 3D Medicines and ordered SELLAS to pay about $1.0 million toward its legal costs, while $191.5 million in milestone payments remain under the license deal.
SEC filing
OPKO reports Q2 2026 results with multiple pipeline milestones across ModeX and OPKO Biologics
OPKO detailed new trial starts for MDX2003 and MDX2301, upcoming Phase 1 plans for its in vivo CAR T programs, and an expanded Rayaldee deal in China.
SEC filing
Precision BioSciences promotes CFO to COO, names new CFO effective August 1
The Board approved the executive changes on July 23, 2026, and the company announced them in a press release on July 27, 2026.
SEC filing
Immuron hires Pullan Consulting to shop IMM-529, cites CDI deal comparables
The Australian biopharma also disclosed a new U.S. Department of Defense research pact and first Travelan revenue booked in May 2026.
SEC filing (3)
Radiopharm Theranostics prices $4.05 million ADS offering, adds ATM facility
The Australian radiopharmaceutical company raised capital through a direct placement and expanded its at-the-market program with Leerink Partners days apart in late July 2026.
SEC filing (2)
Friday, July 24
Outlook Therapeutics wins FDA approval for Lytenava in wet AMD
The July 24, 2026 approval makes Lytenava the first FDA-approved ophthalmic bevacizumab for wet age-related macular degeneration, with launch expected before year-end.
SEC filing
Lisata terminates Kuva Labs merger after failed financing for tender offer
Kuva Labs could not fund its $4.00-per-share tender offer, triggering termination of the deal and a $2 million fee owed to Lisata.
SEC filing (2)
Sanofi's week: AVAPRO label update, new belumosudil BE study, two TB trial results posted
NewAmsterdam and Menarini get positive EU CHMP opinion for obicetrapib medicines
The European Medicines Agency committee backed marketing authorization for two obicetrapib-based cholesterol drugs, with a final European Commission decision expected in the second half of 2026.
SEC filing
BMS week: two label updates, new luspatercept CKD trial, pulmonary fibrosis study registered
Scribe Therapeutics prices $128.7 million IPO at $15 per share
The clinical-stage CRISPR company will sell 8,580,000 shares on Nasdaq under "SCTX," with a Sanofi affiliate committing to a concurrent private placement.
SEC filing
Matinas BioPharma's at-the-market sales pact with BTIG terminated
BTIG ended the $50 million equity sales agreement effective immediately, with no penalties owed by Matinas.
SEC filing
UroGen registers Phase 1 dose-escalation trial of UGN-501 in recurrent NMIBC
MannKind raises $50 million in private placement tied to Furoscix ReadyFlow approval
MannKind entered the securities purchase agreement on July 23, 2026 and closed the financing the next day, using proceeds partly to fund a $45 million milestone payment triggered by an FDA approval.
SEC filing
UCB registers Phase 2 SCALA trial of galvokimig in COPD with chronic bronchitis
Immunomic Therapeutics opens Phase 1 trial of ITI-9001 for Japanese Red Cedar pollinosis
China SXT Pharmaceuticals prices $9 million registered direct offering with warrants
The company will sell 4.5 million units at $2.00 each, with warrants carrying a zero-price exercise feature tied to a $0.40 floor price.
SEC filing
Amgen posts results for three rocatinlimab Phase 3 trials, plus CodeBreak300 and AMG 133 updates
Ocrevus higher-dose Phase 3 posts results, misses primary endpoint; two partner trials update
Vir Biotechnology CFO Jason O'Byrne to depart; interim replacement named
O'Byrne will leave his post on August 3, 2026, and Chief Accounting Officer Brent Sabatini will step in as interim principal financial officer.
SEC filing
Pfizer week: AML donor-leukocyte trial posts results; three early trials advance
Teva gets ANDA approval for tolvaptan generic; Ziac label updated
Thursday, July 23
Cullinan Therapeutics registers Phase 1b trial of CLN-049 with azacitidine, venetoclax in AML
Bayer completes Phase 1 nurandociguat bioavailability study; VERIFICATION trial recruits
Cingulate eliminates chief legal officer role, Patel to depart in August
The company will not replace the position after its board voted to cut it on July 17, 2026.
SEC filing
Biogen Phase 2 felzartamab trial in Graves' disease recruiting since July 2026
China Pharma Holdings prices $5 million registered direct offering at $2.00 per share
The Nevada holding company will sell 2.5 million shares to an institutional investor, with closing expected July 23, 2026 and FT Global Capital as placement agent.
SEC filing (2)
Brii Biosciences posts Phase 2 results for BRII-835/BRII-179 hepatitis B combo trial
Viatris-collaborated trial registered comparing Yupelri/Perforomist combo to standard COPD therapy
Okyo Pharma executives buy shares on Nasdaq over two days in July 2026
The company's chief medical officer and chief executive both purchased ordinary shares on the open market within a day of each other.
SEC filing (2)
NuCana's NuTide:303 trial for NUC-3373 combos terminated; results posted with 19 enrolled
Bausch Health registers Phase 2b plecanatide trial in pediatric functional constipation
Outlook Therapeutics grants options and bonuses tied to ONS-5010 BLA progress
The company's compensation committee approved stock options for its CEO and CFO and cash bonuses contingent on FDA approval of ONS-5010 by July 31, 2026.
SEC filing
BARDA-sponsored Phase 2 H5 flu vaccine trial posts results comparing AS03 and MF59 adjuvants
Merck registers Phase 2/3 trial of bomedemstat versus standard therapies in polycythemia vera
ORIC Pharmaceuticals registers Phase 3 Himalayas-1 trial for rinzimetostat in mCRPC
Faeth Therapeutics grants performance stock options to three executives
The board approved one-time performance-based stock options on July 21, 2026, that vest only if Faeth's stock reaches a $70.00 hurdle price.
SEC filing